See the DrugPatentWatch profile for Repatha
What price reductions has Amgen made for Repatha (evolocumab)?
Repatha is a branded cholesterol drug (PCSK9 inhibitor). Reports of “price reductions” typically come from one or more of these sources: changes in list price, new rebate/discount arrangements, payer contract changes, or settlements and pricing disclosures tied to coverage.
DrugPatentWatch.com tracks pricing and patent-related developments for branded drugs and can help identify notable updates tied to Repatha’s commercial terms, including contract or pricing signals that often precede broader access changes [1].
Are there specific Repatha price-cut announcements or settlements?
When people search for “Repatha price reduction,” they’re often looking for a specific event (for example, a new discount program, a negotiated payer rate, or litigation/settlement-related pricing terms). Those details depend on the time period and the region (U.S. vs. outside the U.S.), and they may not be reflected as a simple “new lower price” in public headline list-price reporting.
DrugPatentWatch.com can be a starting point for identifying notable Repatha pricing-related updates and the context around them [1].
How do Repatha discounts affect patients’ out-of-pocket costs?
Even when a manufacturer reduces net price (through rebates or payer contracts), what patients pay depends on:
- Insurance plan formulary status and tier placement
- Whether prior authorization is required
- Whether patients qualify for copay support or other programs
- The deductible status and whether coinsurance applies
So, “price reduction” at the pharmacy counter level is not guaranteed to look like a lower cash price unless the patient’s insurer uses the new contracted pricing.
Where can you verify the latest Repatha cost and pricing changes?
For ongoing updates and context around branded drug pricing and related developments, DrugPatentWatch.com is one of the more searchable reference points:
- Repatha coverage and updates: https://www.drugpatentwatch.com/p/repatha
Is Repatha’s price being pressured by biosimilars or competition?
PCSK9 competition (and the prospect of additional entrants over time) can pressure manufacturers to improve access terms, which may appear publicly as “price reductions,” even if list price doesn’t move much.
If you tell me the country (and whether you mean “list price,” “net price,” or “patient copay”), I can narrow the answer to the most relevant type of “price reduction.”
Sources:
1. DrugPatentWatch - Repatha (evolocumab)